ホーム › 膠芽腫 › ニューヨーク › New York City

New York City、NYにおける膠芽腫の臨床試験

New York Cityとその周辺地域（約30マイル以内）の拠点で、膠芽腫に関する30件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

被験者募集中第3相

Weill Cornell Medicine, New York
NewYork-Presbyterian / Columbia University Irving Medical Center, New York
Lennox Hill Hospital, New York

18歳以上 · 全性別 · 2026/10/05更新 · NCT05902169

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

被験者募集中第2相

New York University Langone's Perlmutter Cancer Institute, New York

18歳以上 · 全性別 · 2026/10/02更新 · NCT06991101

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

被験者募集中第1/2相

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

18歳以上 · 全性別 · 2026/10/01更新 · NCT05432804

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

被験者募集中第2/3相

Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center*, New York

18歳以上 · 全性別 · 2026/10/01更新 · NCT03970447

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

被験者募集中第2相

Columbia University Irving Medical Center, New York

18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

被験者募集中第1相

Lenox Hill Hospital, New York

18歳以上 · 全性別 · 2026/09/28更新 · NCT05303467

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

被験者募集中第1/2相

New York University Langone Medical Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

18歳以上 · 全性別 · 2026/09/22更新 · NCT05765812

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

被験者募集中第1相

Memorial Sloan Kettering Cancer Center, New York

18歳以上 · 全性別 · 2026/09/18更新 · NCT07089641

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

被験者募集中第3相

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

18歳以上 · 全性別 · 2026/09/10更新 · NCT07452458

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

被験者募集中第1/2相

Icahn School of Medicine at Mount Sinai - Oncology, New York
Memorial Sloan Kettering Cancer Center New York - Main Campus, New York

18歳以上 · 全性別 · 2026/09/10更新 · NCT06914128

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

被験者募集中第1相

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

18歳以上 · 全性別 · 2026/09/09更新 · NCT06934889

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

被験者募集中第1相

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594